The shadow of generic competition has consistently loomed above copyright’s famous drug, Sildenafil, triggering questions about the future of similar pharmaceutical stakes. While early years saw substantial gains, the exclusivity end has opened the way for less expensive substitutes, likely reducing earnings and creating a real hazard for shareho